Mdxhealth Earnings Call: Prostate Pivot Amid Pressure

Mdxhealth S.A. ((MDXH)) has held its Q1 earnings call. Read on for the main highlights of the call.

Mdxhealth’s latest earnings call delivered a cautiously optimistic tone as management doubled down on its high‑growth prostate cancer franchise while acknowledging meaningful near‑term headwinds. Executives framed the exit of the Resolve UTI business and lab closure as proactive moves to protect capital and focus on scalable oncology assets, yet investors were reminded of margin pressure, wider losses, and Medicare recoupment risk.

Prostate Cancer Revenue Growth Holds Despite Turbulence

Pro forma Q1 revenue from Mdxhealth’s core prostate cancer operations reached $23.9 million, up 11% year over year and excluding the Resolve business. Management pointed to this growth as evidence that its commercial strategy is gaining traction, even as the company works through integration noise and volumes that were uneven across its test portfolio.

Raised 2026 Revenue Target Signals Confidence

The company set 2026 revenue guidance for its core cancer business at $110 million to $115 million, excluding Resolve. That outlook implies 20% to 26% annual growth, signaling management’s conviction that the prostate-focused portfolio can scale meaningfully despite current cost pressures and operational challenges.

ExoDx Integration Drives Focused Prostate Franchise

Mdxhealth completed Exo‑driven strategic territory mapping and cross‑training for its expanded sales force in Q1, aligning reps around a unified prostate cancer offering. The company successfully migrated SelectMDx customers onto ExoDx, a move that simplifies the menu to Confirm, GPS, and ExoDx and is expected to improve sales efficiency over time.

AI Initiatives Aim to Deepen Clinical Differentiation

Management unveiled a company‑wide AI initiative, including partnerships to build an AI‑enabled data platform across its diagnostics. The ongoing PROTECT trial with the University of Oxford now incorporates AI‑enhanced endpoints to sharpen the prognostic power of GPS, which could support premium positioning and long‑term competitive advantage.

Liquidity Cushion Solid but Narrowing Post Earn-Out

As of March 31, Mdxhealth reported cash and cash equivalents of $43.2 million, providing a reasonable short‑term buffer. However, a $15 million earn‑out payment made on April 15 reduces pro forma cash to $28.2 million, tightening the company’s liquidity and heightening the importance of disciplined execution and cost control.

Multi-Year Turnaround Highlights Structural Progress

Leadership emphasized the scale of the transformation since 2019, when revenue was just $11 million versus $108 million in 2025. Gross margins have climbed from the 20% range to the mid‑60s and the company achieved adjusted EBITDA profitability before the ExoDx purchase, underscoring that many current headwinds stem from integration and portfolio reshaping, not demand.

Resolve UTI Exit and Lab Closure Mark Strategic Retreat

Mdxhealth decided to discontinue its Resolve UTI test and shut down the Plano, Texas laboratory amid mounting reimbursement uncertainty. The move will affect thousands of patients and trigger restructuring and wind‑down costs, but management argues that redeploying resources to higher‑growth cancer diagnostics will create more durable value for shareholders.

Medicare Recoupment Notice Adds Legal and Cash Risk

Novitas, a Medicare contractor, issued a notice that it may seek retrospective recoupment of up to $10.4 million tied to historical Resolve claims. The company maintains the notice is without merit and plans to pursue a full appeals process, warning that resolution could be lengthy and that the ultimate financial impact remains uncertain.

Margins Slip as Test Mix Shifts Toward Tissue

Pro forma gross margin for the core business was 62.9% in Q1 2026, down from 68.0% a year earlier, a drop of about 5.1 percentage points. Management attributed most of the compression to a heavier mix of tissue‑based tests versus liquid assays, a trend investors will watch closely given its implications for profitability.

Operating Loss Widens with ExoDx Integration Costs

The pro forma operating loss excluding Resolve increased to $7.9 million in Q1 2026, compared with $4.7 million in the prior‑year period. Executives tied the deterioration mainly to costs associated with adding and integrating the ExoDx business, suggesting operating leverage could improve once the combined platform is fully optimized.

Net Loss Flat but Liquidity Cushion Under Pressure

Statutory net loss for the quarter was $8.9 million, while pro forma net loss excluding Resolve was $9.4 million, essentially unchanged from $9.3 million a year ago. Still, the combination of ongoing losses, the earn‑out payment, and potential Medicare recoupment underscores that the balance sheet leaves limited room for missteps.

Tissue Volume Volatility Underscores Execution Risk

Management described tissue‑based testing volumes as choppy against a difficult comparison, citing integration distractions, customer mapping, and shifts in utilization as contributing factors. They expect tissue volumes to accelerate sequentially as integration stabilizes, but acknowledged that near‑term execution risk remains elevated for this part of the franchise.

Guidance Underscores Growth Ambition Amid Headwinds

Looking ahead, Mdxhealth is guiding to $110 million to $115 million in 2026 revenue for its core prostate cancer business, targeting roughly 20% to 26% growth despite lower gross margins and higher operating expenses. Management is betting that AI‑enabled innovation, streamlined product focus, and full realization of ExoDx synergies will offset integration drag, volume volatility, and reimbursement uncertainty.

Mdxhealth’s earnings call painted a story of a diagnostics company in transition, leaning into its prostate cancer strengths while exiting a risky side business and absorbing integration pain. Investors are left weighing the attractive growth and innovation narrative against compressed margins, wider losses, and regulatory overhang, with execution over the next few quarters likely to determine whether the bullish 2026 targets are achievable.